NCT01767623View on ClinicalTrials.gov

A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

August 20, 2013

Primary Completion Date

April 20, 2017

Study Completion Date

April 20, 2017

Conditions
Neoplasms
Interventions
DRUG

Vemurafenib

Vemurafenib orally BID 960 or 720 mg.

Trial Locations (8)

3199

Peninsula and South Eastern Haematology and Oncology Grou, Frankston

11527

District General Hospital of Athens Laiko; 1st Internal Medicine Clinic, Athens

31096

Rambam Health Care Campus, Haifa

35040

Ege University Medicine Develoment and Pharmacokinetics Research Center; Pulmonary Diseases, Izmir

64239

Tel Aviv Sourasky Medical Center, Tel Aviv

92008

California Cancer Associates for Research & Excellence, Inc., Encinitas

350040

"SBIH Clinical Oncological Dispensary # 1; Chemotherapy department #1 and #2", Krasnodar

CF14 2TL

Velindre Cancer Centre, Cardiff

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01767623 - A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants | Biotech Hunter | Biotech Hunter